摘要
目的:探讨溃疡性结肠炎(ulcerative colitis,UC)的临床及实验室特点、治疗和疗效.方法:收集2012-07/2014-07大连医科大学附属第一医院诊治的UC患者115例,对其临床资料、实验室检查结果及治疗进行回顾性分析.结果:11 5例U C中,男女比例为1.5 6∶1.0 0(P<0.0 5),发病高峰年龄为5 0-5 9岁(27.83%),以轻中度为主(83.48%),临床类型以慢性复发型(68.70%)为主,主要症状有黏液脓血便(83.48%)和腹痛(72.17%),病变部位以全结肠(33.04%)为主.血小板(platelet,PLT)和白细胞(white blood cell,WBC)水平与UC病情严重程度有关,病情越重,其水平越高(均P<0.05).英夫利昔单抗治疗中重度U C缓解率为50%,治疗后血沉(e r y t h r o c y t e s e d i m e n t a t i o n r a t e,E S R)、C反应蛋白(C-reactive protein,CRP)较治疗前明显降低(P<0.05).结论:UC病变范围广泛,PLT及WBC可用来评价UC病情严重性,英夫利昔单抗治疗中重度UC疗效确切.
AIM： To analyze the clinical and laboratory characteristics, treatment and curative effect of ulcerative colitis（UC）.METHODS： Clinical data for 115 patients with UC treated at our hospital from July 2012 to July2014 were studied retrospectively.RESULTS： The male/female ratio was 1.56∶1（P 〈 0.05）, and the peak age of onset was 50 to59 years（27.83%）. Most of the hospitalized UC patients had mild or moderate disease（83.48%）,and 68.70% had chronic relapsing disease. Major symptoms were mucopurulent bloody stool（83.48%） and abdominal pain（72.17%）. The entire colon was involved in about 33.04% of cases.The counts of platelets（PLT） or white blood cells（WBC） were correlated well with the severity of UC. The remission rate with infliximab to treat active moderate to severe UC was 50%, and erythrocyte sedimentation rate（ESR） and C-reactiveprotein（CRP） decreased significantly after treatment with infliximab（P 〈 0.05）.CONCLUSION： The lesions of UC are extensive.PLT and WBC can be used as markers to assess the severity of UC. Infliximab has appreciated effects in the treatment of active moderate to severe UC.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第33期5188-5192,共5页
World Chinese Journal of Digestology
